Renewed COVID-19 headwinds mute overall Q3 results, however, the soft tissue repair segment remains resilient
Impact of the Delta variant was felt broadly across OrthoBio, with virtually all publicly traded companies observing a reduction in surgical volume (relative to forecast) directly attributable to a resurgence of COVID-19. Overall, OrthoBio revenue declined, primarily driven by a sharp reduction in Bone Replacement revenue. Several companies noted the decrease in surgical volumes was most acute in August and September due to shortages in hospital staffing. Weakness was most closely tied to deferrable, elective, complex spine procedures.
Among the many topics covered in detail in our comprehensive Q321 OrthoBio Market Recap* are:
- Complete Q321 OrthoBio Market Overview
- SmartTRAK's Expert Analysis and Insights
- All Market News including Revenues, Data, Charts and Shares
- Notable Commentary
- New Product Introductions
- Regulatory Approvals
- M&A/Deals/Financing
Smith & Nephew* (SNN) and the Soft Tissue Replacement segment was the lone bright spot in Q3 (up +20.2%), driven by continued market acceptance and adoption of SNN’s REGENETEN product. SNN was bullish on its ...
*The entire unedited article and these links can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK has launched five new modules in 2021. Click here to see details of all the exciting new content now available on SmartTRAK.
